Johnson & Johnson (JNJ -0.92%) primarily generates revenue by developing and selling pharmaceutical treatments and medical technology products worldwide.

It recently secured two regulatory approvals for upcoming medical treatments, and it launched a cardiovascular catheter device in the United States.

Novo Nordisk (NVO -2.75%) earns its revenue by developing and producing specialized pharmaceutical therapies for diabetes, obesity care, and rare blood disorders.

It received European marketing authorization for a hemophilia treatment, while facing a latest regulatory requirement to add warning labels to certain existing medications.

Revenue here refers to the data provider's standardized income-statement revenue line item, which serves as a baseline indicator of total sales volume and overall market demand.

Sources indicate that johnson & Johnson vs. Novo Nordisk Revenue over the last 8 quarters. Figures: Novo Nordisk shown in U.S. dollars, converted from Danish kroner.

The first thing to check for when examining a company's revenue trend is seasonality: some times of the year have stronger buying patterns than others. There usually is some seasonality for every business.

There can be seasonality in healthcare stocks, often seen as consumers spend more in the fourth calendar quarter to take advantage of insurance deductibles being met. We see some seasonality in Johnson & Johnson's business from that, with Q1 revenue ticking down compared to prior quarters. In such cases, compare year-over-year results, so Q1 2026 compared to Q1 2025 shows a rise in revenue.

Even wth that seasonality, JNJ demonstrates positive revenue growth overall in the chart, and no wonder--the business has 28 products and platforms that generate more than $1 billion in annual revenue.

Given the nature of its primary product, GLP-1s, which need to be taken continuously, Novo Nordisk doesn't see a lot of seasonality in its business. Yet the chart shows that the company is struggling to find sales momentum as competitors catch up with their weight loss offerings.

According to recent reports, revenue trend is the most obvious figure for investors to examine when considering a stock. The chart indicates that one business is thriving while the other is seeking to regain its footing.

Recent findings suggest that data source: Financial Modeling Prep. Novo Nordisk's figures are converted from Danish kroner to U.S. dollars. Data as of Nov. 16, 2026.

According to recent reports, when our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 823%* β€” a market-crushing outperformance compared to 209% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

*Stock Advisor returns as of November 17, 2026.

According to recent reports, *Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Industry observers note that invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

β†’ Read original article